<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Stepwise asthma management in children 4 to 11 years old</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Stepwise asthma management in children 4 to 11 years old</h1>
<div class="graphic"><div class="figure"><div class="ttl">Stepwise asthma management in children 4 to 11 years old</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1" colspan="2">NAEPP*<br/> (5 to 11 years old)</td> <td class="subtitle1" colspan="2">GINA<br/> (6 to 11 years old)</td> <td class="subtitle1">Our approach<br/> (4 to 11 years old)</td> </tr> <tr class="divider_bottom"> <td class="subtitle2">Asthma symptoms/impact</td> <td class="subtitle2">Therapy</td> <td class="subtitle2">Asthma symptoms</td> <td class="subtitle2">Therapy<br/> (all steps include SABA as needed)</td> <td class="subtitle2">Therapy</td> </tr> <tr class="divider_bottom"> <td>Intermittent: <ul class="decimal_heading"> <li>Daytime symptoms ≤2 days/week</li> <li>Nocturnal awakenings ≤2/month</li> <li>No interference with activities</li> <li>Normal FEV<sub>1</sub> and FEV<sub>1</sub>/FVC</li> <li>Exacerbations ≤1/year</li> </ul> </td> <td><strong>Step 1</strong> <ul class="decimal_heading"> <li>SABA as needed</li> </ul> </td> <td> <ul> <li>Infrequent asthma symptoms (eg, &lt;2 times/month)</li> </ul> </td> <td> <p><strong>Step 1</strong></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>Low-dose ICS whenever SABA is used</li> </ul> <p class="extra_spacing_top">Alternatives:</p> <ul class="decimal_heading"> <li>Daily low-dose ICS</li> </ul> </td> <td> <p><strong>Step 1</strong></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>SABA as needed</li> </ul> <p class="extra_spacing_top">Alternatives:</p> <ul class="decimal_heading"> <li>Low-dose ICS whenever SABA used</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Mild persistent: <ul class="decimal_heading"> <li>Daytime symptoms &gt;2 but &lt;7 days/week</li> <li>Nocturnal awakenings 3 to 4/month</li> <li>Minor interference with activities</li> <li>Normal FEV<sub>1</sub> and FEV<sub>1</sub>/FVC</li> <li>Exacerbations ≥2/year</li> </ul> </td> <td> <p><strong>Step 2</strong><sup>¶</sup></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>Daily low-dose ICS and SABA as needed</li> </ul> <p class="extra_spacing_top">Alternative:</p> <ul class="decimal_heading"> <li>Daily LTRA and SABA as needed</li> </ul> </td> <td> <ul> <li>Asthma symptoms or need for reliever inhaler ≥2 times/month</li> </ul> </td> <td> <p><strong>Step 2</strong></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>Daily low-dose ICS</li> </ul> <p class="extra_spacing_top">Alternatives:</p> <ul class="decimal_heading"> <li>Daily LTRA</li> </ul> <p class="indent1">or</p> <ul class="decimal_heading"> <li>Low-dose ICS whenever SABA is used</li> </ul> </td> <td> <p><strong>Step 2</strong></p> <p class="extra_spacing_top">Preferred (includes SABA as needed):</p> <ul class="decimal_heading"> <li>Daily low-dose ICS</li> </ul> <p class="extra_spacing_top">Alternatives (includes SABA as needed):</p> <ul class="decimal_heading"> <li>Daily LTRA</li> </ul> <p class="indent1">or</p> <ul class="decimal_heading"> <li>Low-dose ICS whenever SABA used</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Moderate persistent: <ul class="decimal_heading"> <li>Daily symptoms</li> <li>Nocturnal awakenings &gt;1/week but not daily</li> <li>Daily SABA use</li> <li>Some activity limitation</li> <li>FEV<sub>1</sub> 60 to 80% predicted; FEV<sub>1</sub>/FVC below normal</li> <li>Exacerbations ≥2/year</li> </ul> </td> <td> <p><strong>Step 3</strong><sup>¶</sup></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>Daily and as needed low-dose ICS-formoterol</li> </ul> <p class="extra_spacing_top">Alternative:</p> <ul class="decimal_heading"> <li>Daily medium-dose ICS and as needed SABA</li> </ul> <p class="indent1">or</p> <ul class="decimal_heading"> <li>Daily low-dose ICS-LABA or low-dose ICS plus LTRA and as needed SABA</li> </ul> </td> <td> <ul> <li>Troublesome asthma symptoms most days</li> </ul> or <ul> <li>Waking due to asthma ≥1 time/month (also assess risk factors for exacerbations)</li> </ul> </td> <td> <p><strong>Step 3</strong></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>Daily low-dose ICS-LABA</li> </ul> <p class="indent1">or</p> <ul class="decimal_heading"> <li>Daily medium-dose ICS</li> </ul> <p class="extra_spacing_top">Alternative:</p> <ul class="decimal_heading"> <li>Daily low-dose ICS plus LTRA</li> </ul> </td> <td> <p><strong>Step 3</strong></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>Daily and as- needed low-dose ICS-formoterol (fast-onset LABA)</li> </ul> <p class="extra_spacing_top">Alternatives (includes SABA as needed):</p> <ul class="decimal_heading"> <li>Daily low-dose ICS-LABA (slower- onset LABA)</li> </ul> <p class="indent1">or</p> <ul class="decimal_heading"> <li>Daily medium-dose ICS</li> </ul> <p class="indent1">or</p> <ul class="decimal_heading"> <li>Daily low-dose ICS plus LTRA</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Severe persistent: <ul class="decimal_heading"> <li>Symptoms throughout the day</li> <li>Nocturnal awakenings most nights</li> <li>Need for SABA several times/day</li> <li>Extreme limitation in activity</li> <li>FEV<sub>1</sub> &lt;60% predicted; FEV<sub>1</sub>/FVC below normal</li> <li>Exacerbations ≥2/year</li> </ul> </td> <td> <p><strong>Step 4</strong><sup>¶</sup></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>Daily and as needed medium-dose ICS-formoterol</li> </ul> <p class="extra_spacing_top">Alternative:</p> <ul class="decimal_heading"> <li>Daily medium-dose ICS-LABA and as needed SABA</li> </ul> <p class="indent1">or</p> <ul class="decimal_heading"> <li>Daily medium-dose ICS plus LTRA and as needed SABA</li> </ul> </td> <td> <ul> <li>Severe asthma</li> </ul> </td> <td> <p><strong>Step 4</strong><sup>¶</sup></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>Daily medium-dose ICS-LABA</li> </ul> <p class="indent1">or</p> <ul class="decimal_heading"> <li>Daily low-dose ICS plus LTRA</li> </ul> <p class="extra_spacing_top">Alternatives:</p> <ul class="decimal_heading"> <li>Daily medium-dose ICS-LABA and add-on tiotropium or LTRA</li> </ul> </td> <td> <p><strong>Step 4</strong></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>Daily and as needed medium-dose ICS-formoterol (fast-onset LABA)</li> </ul> <p class="extra_spacing_top">Alternatives (includes SABA as needed):</p> <ul class="decimal_heading"> <li>Daily medium-dose ICS-LABA (slower- onset LABA)</li> </ul> <p class="indent1">or</p> <ul class="decimal_heading"> <li>Daily high-dose ICS</li> </ul> <p class="indent1">or</p> <ul class="decimal_heading"> <li>Daily medium-dose ICS plus LTRA</li> </ul> <p class="indent1">or</p> <ul class="decimal_heading"> <li>Daily medium-dose ICS-LABA and add-on tiotropium or LTRA</li> </ul> </td> </tr> <tr> <td rowspan="2"> <ul> <li>Step-up therapy for severe asthma that is poorly controlled</li> </ul> </td> <td> <p><strong>Step 5</strong></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>Daily high-dose ICS-LABA and as needed SABA</li> </ul> <p class="extra_spacing_top">Alternative:</p> <ul class="decimal_heading"> <li>Daily high-dose ICS plus LTRA and as needed SABA</li> </ul> <p class="extra_spacing_top">Add-on therapy:</p> <ul class="decimal_heading"> <li>A biologic agent (eg, omalizumab, mepolizumab) is an additional option for patients ≥6 years of age</li> </ul> </td> <td rowspan="2"> <ul> <li>Step-up therapy for severe asthma that is poorly controlled</li> </ul> </td> <td> <p><strong>Step 5</strong></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>Daily medium-dose ICS-LABA and assess for possible high-dose ICS-LABA or add-on therapy (anti-IgE or anti-IL4R)</li> </ul> <p class="extra_spacing_top">Alternative add-on therapies:</p> <ul class="decimal_heading"> <li>Anti-IL-5R; low-dose OCS only as last resort</li> </ul> </td> <td> <p><strong>Step 5</strong></p> <p class="extra_spacing_top">Preferred (includes SABA as needed):</p> <ul class="decimal_heading"> <li>Daily medium-dose ICS-LABA and tiotropium (in children ≥6 years of age)</li> </ul> <p class="indent1">or</p> <ul class="decimal_heading"> <li>Daily high-dose ICS-LABA (in children 4 to &lt;6 years of age)</li> </ul> <p class="extra_spacing_top">Alternatives (includes SABA as needed):</p> <ul class="decimal_heading"> <li>Daily medium-dose ICS-LABA and LTRA</li> </ul> <p class="indent1">or</p> <ul class="decimal_heading"> <li>Daily high-dose ICS-LABA</li> </ul> <p class="indent1">or</p> <ul class="decimal_heading"> <li>Daily high-dose ICS plus LTRA</li> </ul> <p class="extra_spacing_top">Add-on therapy:</p> <ul class="decimal_heading"> <li>A biologic agent (eg, omalizumab [anti-IgE], dupilumab [anti-IL-4R], or mepolizumab [anti-IL-5R]) is an additional option for patients ≥6 years of age</li> </ul> </td> </tr> <tr> <td> <p><strong>Step 6</strong></p> <p class="extra_spacing_top">Preferred:</p> <ul class="decimal_heading"> <li>Daily high-dose ICS-LABA plus OCS and as needed SABA</li> </ul> <p class="extra_spacing_top">Alternative:</p> <ul class="decimal_heading"> <li>Daily high-dose ICS plus LTRA and OCS and as needed SABA</li> </ul> <p class="extra_spacing_top">Add-on therapy:</p> <ul class="decimal_heading"> <li>A biologic agent (eg, omalizumab, mepolizumab) is an additional option for patients ≥6 years of age</li> </ul> </td> <td> </td> <td><strong>Step 6</strong> <ul class="decimal_heading"> <li>One of the above options plus OCS</li> <li>A biologic agent (eg, omalizumab, dupilumab, or mepolizumab) is an additional option for patients ≥6 years of age</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Initial therapies are noted above. A higher level of initial therapy, with concurrent use of OCS in some cases, may be chosen if the patient presents with an acute exacerbation. Treatment may be stepped down if asthma is well controlled for at least 3 months and is stepped up 1 or 2 steps if asthma is not well controlled or is very poorly controlled.</div><div class="graphic_footnotes"><p>NAEPP: National Asthma Education and Prevention Program; GINA: Global Initiative for Asthma; SABA: short-acting beta agonist; FEV<sub>1</sub>: forced expiratory volume in 1 second; FVC: forced vital capacity; ICS: inhaled corticosteroid (glucocorticoid); LTRA: leukotriene receptor antagonist; LABA: long-acting beta agonist; OCS: oral corticosteroid (glucocorticoid); IgE: immunoglobulin E; IL-5R: interleukin 5 receptor.</p>
<p>* Theophylline, cromolyn, and nedocromil were not included in table even though they were included in NAEPP. They are rarely used due availability of more effective options.</p>
¶ Subcutaneous allergen immunotherapy is suggested as adjunctive treatment in patients with well-controlled asthma and environmental allergies.</div><div class="graphic_reference">References:
<ol>
<li>National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. 2020 Focused updates to the asthma management guidelines. National Heart, Lung, and Blood Institute, 2007. Available at: <a href="https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines" target="_blank">https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines</a> (Accessed on December 16, 2020).</li>
<li>Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Available at: <a href="http://www.ginasthma.org" target="_blank">www.ginasthma.org</a> (Accessed on October 27, 2022).</li>
</ol></div><div id="graphicVersion">Graphic 127786 Version 6.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
